Anixa Biosciences (NASDAQ:ANIX) posted its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02, Fidelity Earnings reports.
NASDAQ:ANIX opened at $4.33 on Friday. The stock has a market cap of $136.10 million, a P/E ratio of -3.83 and a beta of 1.41. Anixa Biosciences has a twelve month low of $1.70 and a twelve month high of $8.09. The stock’s 50 day moving average is $4.32.
In related news, Director Emily Gottschalk bought 10,000 shares of the company’s stock in a transaction on Friday, April 23rd. The shares were bought at an average price of $4.49 per share, with a total value of $44,900.00. In the last three months, insiders have acquired 30,000 shares of company stock worth $137,150. 19.80% of the stock is owned by insiders.
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.
See Also: Options Trading – What is a Straddle?
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.